Cargando…

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

BACKGROUND: Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forbes, John F, Sestak, Ivana, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael, Holcombe, Chris, Coleman, Robert E, Jones, Louise, Ellis, Ian, Cuzick, Jack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769326/ https://www.ncbi.nlm.nih.gov/pubmed/26686313 http://dx.doi.org/10.1016/S0140-6736(15)01129-0

Ejemplares similares

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
por: Cuzick, Jack, et al.
Publicado: (2020)

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
por: Cuzick, Jack, et al.
Publicado: (2010)

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
por: Cuzick, Jack, et al.
Publicado: (2015)

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
por: Sestak, Ivana, et al.
Publicado: (2021)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
por: Sestak, I, et al.
Publicado: (2012)

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
por: Sestak, I, et al.
Publicado: (2018)

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
por: Smith, Samuel George, et al.
Publicado: (2017)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005)

Effects of cyclin D(1 )gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
por: Lundgren, Katja, et al.
Publicado: (2012)

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019)

A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
por: Pinder, S E, et al.
Publicado: (2010)

Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors
por: Eisner, Alvin, et al.
Publicado: (2007)

A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer
por: Lin, Ying, et al.
Publicado: (2014)

Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial
por: Thorat, Mangesh A., et al.
Publicado: (2021)

Ibis
por: Vargas Vila, José María, 1860-1933
Publicado: (1908)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
por: Kemp, Anna, et al.
Publicado: (2014)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

Low-risk DCIS. What is it? Observe or excise?
por: Pinder, Sarah E., et al.
Publicado: (2021)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer
por: Yang, Yan, et al.
Publicado: (2017)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ
por: Lo, Louisa Lisa, et al.
Publicado: (2018)

Multiple bone metastases detected 10 years after mastectomy with silicone reconstruction for DCIS and contralateral augmentation
por: Mori, Ryutaro, et al.
Publicado: (2013)

Vascular density and phenotype around ductal carcinoma in situ (DCIS) of the breast
por: Teo, N B, et al.
Publicado: (2002)

Correlation Between Anthropometric Measures and Biomarker Changes After Neoadjuvant Therapy With Tamoxifen or Anastrozole in Postmenopausal Women With Breast Cancer
por: Cintra, Karine A., et al.
Publicado: (2010)

Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence
por: Barnes, N, et al.
Publicado: (2006)

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)

Is palpable DCIS more aggressive than screen-detected DCIS?
por: Balac, Nina, et al.
Publicado: (2022)

Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer
por: Godina, Christopher, et al.
Publicado: (2023)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer
por: Kaas, R, et al.
Publicado: (2003)

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
por: Smith, Samuel G., et al.
Publicado: (2021)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
por: Jia, Huiqing, et al.
Publicado: (2022)

The Italian Tamoxifen Prevention Trial
por: Bonanni, B., et al.
Publicado: (1999)

Effects of psoralen on the pharmacokinetics of anastrozole in rats
por: Zhang, Yuzhu, et al.
Publicado: (2018)

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials
por: Cuzick, Jack, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jtse1cr0ed1oglkcgla9984jin